Androsta-1,4-diene-3,17-dione
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
897-06-3C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12LUJVUUWNAPIQQI-QAGGRKNESA-NAndrosta-1,4-diene-3,17-dione is a steroid that consists of androstane having double bonds at positions 1 and 4 and two keto groups at positions 3 and 17. It is a 17-oxo steroid, a 3-oxo-Delta(1) steroid and a 3-oxo-Delta(4) steroid. It derives from a hydride of an androstane.
DEA Schedule III Controlled Substance -> Anabolic steroids
Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds
Pharmaceuticals -> Listed in ZINC15
166.5 Ų [M+H]+ [CCS Type: TW]
190.28 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
168.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H302 (35%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P263, P264, P270, P273, P280, P301+P317, P318, P319, P330, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 20 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
DEA schedule III controlled substance
REACH registered substance: Androsta-1,4-diene-3,17-dione (EC: 212-977-2)
用途ボルジオン(Boldione)は、ボルデノンの前駆体であり
説明Androsta-1,4-diene-3,17-dione (Item No. 24081) is an analytical reference standard categorized as an anabolic androgenic steroid. Androsta-1,4-diene-3,17-dione is a precursor in the synthesis of boldenone and has been used to enhance athletic performance. Androsta-1,4-diene-3,17-dione is regulated as a Schedule III compound in the United States. This product is intended for research and forensic applications.
使用Boldenone related steroid; anabolic androgenic steroid
897-06-3DTXSID00862463CHEMBL1078534CHEBI:40799化学的特性White Crystalline Powder
定義ChEBI: A steroid that consists of androstane having double bonds at positions 1 and 4 and two keto groups at positions 3 and 17.